Tempest Therapeutics (TPST) shares fell nearly 20% following the announcement of a private placement agreement to raise up to $6 million. The financing will involve the issuance of approximately 926,000 shares at $2.16 each, alongside warrants for additional shares. This capital infusion aims to bolster the company’s ongoing clinical development and operational needs as it advances its immunotherapy and cell-therapy programs.
The impact on the stock is significant, reflecting investor sentiment amid dilution concerns. Tempest is currently focused on developing treatments for challenging cancers, with its lead candidate, Amezalpat, in a Phase 2 trial for hepatocellular carcinoma. The company’s pipeline also includes promising CAR-T therapies for multiple myeloma and familial adenomatous polyposis, which could drive future growth if successful.
Investors should monitor how this financing affects Tempest’s operational capabilities and clinical timelines, as any delays or setbacks in its drug development could further influence stock performance in the near term.
Source: nasdaq.com